Several companies on Wall Street have seen recent Seeking Alpha analyst activity, including both upgrades and downgrades.

The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company ...

DekaBank Deutsche Girozentrale increased its stake in Regeneron Pharmaceuticals by 4.7% this quarter, now holding 221,176 ...

The Paroxysmal Nocturnal Hemoglobinuria treatment market is experiencing significant expansion, driven by increasing disease awareness, rising preval ...

This was the stock's third consecutive day of gains.

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

A federal judge on Thursday declined to block the bankruptcy sale of genetic testing company 23andMe to its co-founder Anne ...

Utah families who used 23andMe's genetic testing services face unique privacy risks as the biotech company enters bankruptcy proceedings and prepares for sale t ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Interleukin-2 (IL-2) inhibitors are immunosuppressive agents that block the activity of IL-2, a cytokine involved in the activation and proliferation of T cells. The growing prevalence of autoimmune ...